TRANSDERMAL ABSORPTIONSDOSISENHED TIL BEHANDLING AF POSTMENOPAUSESYNDROM OG FREMGANGSMAADE TIL INDGIVELSE

摘要

Transdermal absorption dose units for treating post- menopausal syndrome have been developed, which dose units comprise a supporting layer and an adjacent adhesive polymer layer in which at least a minimum effective daily dose of an oestrogen is microdispersed. At the present moment, preference is given to using the naturally occurring oestrogen 17-β-oestradiol or ethynyloestradiol, or combinations thereof together with a quantity of naturally occurring progestogen or a progestin in order to minimize any possible side-effects. The units employ bioacceptable adhesives and polymers. An additional polymer layer which is in close contact with the oestrogen-containing layer can also be used. Where appropriate, it is also possible to use a separating layer for producing the dose units, with this layer separating the two adhesive polymer layers and allowing the transfer of oestrogen from the first adhesive polymer layer during the treatment. This results in dose units which transdermally release at least minimum daily doses of the oestrogen for at least one day or for a number of days, such as a week. This results, finally, in a process for treating post menopausal syndrome using the novel dose units.